Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more
Oncopeptides AB (ONCO) - Total Liabilities
Latest total liabilities as of September 2025: Skr204.74 Million SEK
Based on the latest financial reports, Oncopeptides AB (ONCO) has total liabilities worth Skr204.74 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oncopeptides AB - Total Liabilities Trend (2014–2024)
This chart illustrates how Oncopeptides AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Oncopeptides AB Competitors by Total Liabilities
The table below lists competitors of Oncopeptides AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gogoro Inc
NASDAQ:GGR
|
USA | $569.75 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$38.52 Million |
|
CHOROKBAEM COMPANY Co. Ltd
KQ:052300
|
Korea | ₩80.01 Billion |
|
Schloss Wachenheim AG
F:SWA
|
Germany | €221.07 Million |
|
Cuprum
SN:CUPRUM
|
Chile | CL$280.71 Billion |
|
Shihlin Development Company Limited
TWO:5324
|
Taiwan | NT$8.54 Billion |
|
Kron Telekomunikasyon Hizmetleri AS
IS:KRONT
|
Turkey | TL402.17 Million |
|
PharmGen Science Inc
KO:004720
|
Korea | ₩83.70 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Oncopeptides AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 31.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncopeptides AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncopeptides AB (2014–2024)
The table below shows the annual total liabilities of Oncopeptides AB from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr189.91 Million | +4.58% |
| 2023-12-31 | Skr181.60 Million | +99.49% |
| 2022-12-31 | Skr91.03 Million | -60.16% |
| 2021-12-31 | Skr228.51 Million | -38.22% |
| 2020-12-31 | Skr369.86 Million | +88.25% |
| 2019-12-31 | Skr196.47 Million | +52.66% |
| 2018-12-31 | Skr128.70 Million | +108.19% |
| 2017-12-31 | Skr61.82 Million | +111.01% |
| 2016-12-31 | Skr29.30 Million | +318.39% |
| 2015-12-31 | Skr7.00 Million | +26.91% |
| 2014-12-31 | Skr5.52 Million | -- |